Anzupgo (delgocitinib) NDC 50222-280

NDC codes

FDA NDC Directory

Product NDC (as listed)50222-280Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50222-0280Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
50222-280-30	50222028030	1 TUBE in 1 CARTON (50222-280-30) / 30 g in 1 TUBEMarketed from Jul 24, 2025
50222-280-91	50222028091	1 TUBE in 1 CARTON (50222-280-91) / 15 g in 1 TUBEMarketed from Jul 24, 2025 · Sample package
50222-280-99	50222028099	1 TUBE in 1 CARTON (50222-280-99) / 5 g in 1 TUBEMarketed from Aug 30, 2025 · Sample package

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Anzupgo
Generic name (nonproprietary): delgocitinib
Active ingredients: Delgocitinib — 20 mg/g
Dosage form: Cream
Route: Topical
Labeler: LEO Pharma, Inc
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 219155
Marketing start: Jul 24, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Janus Kinase Inhibitors (Mechanism)
Identifiers: Product ID 50222-280_91c8e409-94b0-45cd-9845-81fa653a271dSPL ID 91c8e409-94b0-45cd-9845-81fa653a271dSPL set ID a59bf36e-6f04-4b47-b385-8040c95f040cRxCUI 2721167, 2721172UNII 9L0Q8KK220
Pharmacologic class: Janus Kinase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450222028030 followed by a unit qualifier and the quantity

Package 50222-0280-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 10, 2026.

Indications (excerpt from the label)

ANZUPGO is indicated for the topical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. Limitations of Use Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended. ANZUPGO is a Janus kinase (JAK) inhibitor indicated for the topical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. ( 1 ) Limitations of Use: Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended. ( 1 )…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)